Última revisão: 19 Set 2021
Última atualização: 12 Ago 2021

Resumo

Definição

História e exame físico

Principais fatores diagnósticos

  • presença de fatores de risco
  • eritema ou ulceração da mucosa oral
  • dor oral

Outros fatores diagnósticos

  • comprometimento alimentar
  • diarreia
  • febre

Fatores de risco

  • esquemas de quimioterapia intensiva
  • radioterapia na cavidade oral
  • quimiorradiação
  • polimorfismos genéticos em enzimas metabólicas do medicamento

Investigações diagnósticas

Investigações a serem consideradas

  • hemograma completo e diferencial
  • hemoculturas
  • esfregaço superficial da lesão para microscopia
  • cultura fúngica
  • cultura viral ou reação em cadeia da polimerase

Algoritmo de tratamento

Colaboradores

Autores

Rajesh V. Lalla, DDS, PhD, DABOM

Associate Professor

Associate Dean for Research

Section of Oral Medicine

University of Connecticut School of Dental Medicine

Farmington

CT

Declarações

RVL serves as a consultant for Galera Therapeutics, Ingalfarma, Mundipharma and Sucampo Pharma, and has received research funding from Onxeo, Sucampo Pharma, Galera Therapeutics and Novartis.

Ourania Nicolatou-Galitis, DDS, MSc, DrDent

Professor

Hospital Dentistry

National & Kapodistrian University of Athens

Athens

Greece

Declarações

ONG has received fees from Angelini pharma to author a review article on oral mucositis. ONG is an author of several references cited in this topic.

Nikolaos Tsoukalas, MD, MSc, PhD

Medical Oncologist

Associate Director

Department of Oncology

401 General Military Hospital

Athens

Greece

Declarações

NT declares that he has no competing interests.

Agradecimentos

Professor Ourania Nicolatou-Galitis and Dr Nikolaos Tsoukalas would like to gratefully acknowledge Dr Eleni Arvanitou, who contributed to the updating of this topic, and Dr Rajesh V. Lalla, a previous contributor.

Declarações

EA declares that she has no competing interests. RVL serves as a consultant for Galera Therapeutics, Ingalfarma, Mundipharma and Sucampo Pharma, and has received research funding from Onxeo, Sucampo Pharma, Galera Therapeutics, and Novartis.

Revisores

Michael Brennan, DDS, MHS

Associate Chairman and Oral Medicine Residency Director

Department of Oral Medicine

Carolinas Medical Center

Charlotte

NC

Declarações

MB is an author of a reference cited in this topic. MB is part of the Mucositis Study Group of MASCC/ISOO, and participated in the review of mucositis.

Maria Michelagnoli, MB ChB, MD, FRCPCH

Consultant Pediatric and Adolescent Oncologist

University College London Hospitals

London

UK

Declarações

MM declares that she has no competing interests.

O uso deste conteúdo está sujeito ao nosso aviso legal